Molecular, Genetic and Immunomodulatory Mechanisms in Soft Tissue Sarcoma
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".
Deadline for manuscript submissions: closed (30 November 2021) | Viewed by 7254
Special Issue Editor
Special Issue Information
Dear Colleagues,
Soft tissue sarcomas (STS) are a heterogeneous group of rare malignant neoplasms arising within embryonic mesenchymal tissues during the process of differentiation into cartilage, muscle, blood vessels, nerves, and fat. Diagnosis of sarcoma is based on morphology, immunohistochemistry, and clinicopathological correlation. A better understanding of the molecular biology of pathogenesis is fundamental, as STSs are distinguished by specific molecular aberrations, such as somatic mutations, deletions, gene amplifications, reciprocal translocations, and complex karyotypes. Molecular studies have been critical in providing refinements to morphologic sarcoma classification, at times very challenging, while contributing to diagnostic information, prognostic stratification and predictive insights concerning specific therapies.
All molecular and genetic discoveries have led to a better understanding of the modern concepts of cancer biology, including molecular signals driving tumor growth and permanence, and the molecular pathways involved leading to treatment strategy options for STS. Sustained growth, the evasion of growth suppressors, resistance to death, induction of angiogenesis, and the ability to invade and spread are fundamental tumor characteristics, all of which have underlying molecular correlates that scientists are beginning to uncover and comprehend. However, in addition to molecular and genetic findings, other determinants, such as genomic instability, immunological profile, tumor-promoting inflammation, and deregulation of cellular energy pathways have a critical role in the aggressiveness of sarcomas. Only 15% of STS patients respond in immunotherapy trials; there are no biomarkers predicting the response of STS to checkpoint blockade therapies yet. Therefore, unraveling immunomodulatory mechanisms in STS have the potential to unveil essential insights to immunotherapy approaches.
This Special Issue of IJMS intends to bring together high-quality publications covering several innovating insights on the molecular, genetic and immunomodulatory mechanisms, leading to a better understanding of STS development. These novel aspects may ultimately improve the clinical management of both adult and pediatric STS patients, providing a better clinical understanding, developing safer and more potent targeted therapies, and driving new initiatives to improve their final outcome.
Dr. Gasparini Patrizia
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- soft tissue sarcoma
- pediatric tumors
- rhabdomyosarcoma
- non-rhabdomyosarcoma
- synovial sarcoma
- leiomyosarcoma
- angiosarcoma
- dermatofibrosarcoma protuberans
- epithelioid sarcoma
- gastrointestinal stromal tumor (GIST)
- leiomyosarcoma
- liposarcoma
- malignant peripheral nerve sheath tumor (MPNST)
- myxofibrosarcoma
- solitary fibrous tumor
- undifferentiated (pleomorphic sarcoma)
- molecular genetics
- immune profile
- gene expression
- miRNA
- target therapy
- metastasis
- pediatric oncology
- immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
